Search
Massachusetts Paid Clinical Trials
A listing of 3352 clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 3352
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Massachusetts is currently home to 3352 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)
Recruiting
Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.
Conditions:
Obsessive-Compulsive Disorder
Obsessive Compulsive Disorder
Obsessive Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder (OCD)
Obsessive-compulsive Disorders and Symptoms
Featured Trial
Depression Clinical Studies
Recruiting
Need new medication for depression? Help us study an investigational medication to potentially help people with MDD. Qualified participants may receive reasonable compensation for trial-required travel expenses.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorder
Featured Trial
Bipolar Disorder Study (Medicare Required)
Recruiting
Non-drug Bipolar Depression study for adults with Medicare. If you have Bipolar Disorder, are over the age of 18, and are currently depressed, you may be eligible to take part in this study. If you have tried at least four treatments and not found them helpful, you are a good candidate for this study. All study-related care will be provided at no cost to you.
Conditions:
Bipolar Disorder
Bipolar Depression
Bipolar I Disorder
Depression
Bipolar
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Recruiting
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma Stage IV, Solid Tumor
Supporting Our Caregivers In ADRD Learning (SOCIAL)
Recruiting
Building on limitations of prior research, the investigators developed the Mindful and Self-Compassionate Care Program (MASC) to help caregivers of persons with Alzheimer Disease and Related Dementias (ADRD) manage stress associated with the general caregiver experience including stress stemming from managing challenging patient behaviors. MASC teaches: (1) mindfulness skills; (2) compassion and self-compassion skills; and (3) behavioral management skills. MASC also provides psychoeducation and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Alzheimer's Disease and Related Dementias, Quality of Life, Caregiver Stress
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Investigative Site US225, Boston, Massachusetts
Conditions: Hidradenitis Suppurativa (HS)
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Recruiting
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Solid Tumors
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/21/2024
Locations: The Elliot Lewis Center for Multiple Sclerosis Care Site Number : 8400033, Wellesley, Massachusetts
Conditions: Multiple Sclerosis
Reminder-cue Scanning Training for Homonymous Visual Field Loss
Recruiting
This study will evaluate a new approach to training people with visual field loss to scan when driving
Gender:
All
Ages:
16 years and above
Trial Updated:
06/21/2024
Locations: Schepens Eye Research Institute of Mass Eye and Ear, Boston, Massachusetts
Conditions: Homonymous Hemianopia, Homonymous Quadrantanopia
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Allcutis Research Inc Beverly, Beverly, Massachusetts
Conditions: NonSegmental Vitiligo
An Evaluation of Patient Reported Outcomes and Clinical Outcomes
Recruiting
This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery:
Patient reported outcomes (PRO), using the EQ-5D questionnaire
Clinical outcomes
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Post-Operative Complications in Cardiac Surgery
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
Recruiting
The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
Gender:
All
Ages:
Between 12 years and 130 years
Trial Updated:
06/21/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Hypophosphatasia
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery
Recruiting
The purpose of this study is to evaluate the effect of RBT-1 on reducing the risk of post-operative complications in subjects undergoing cardiac surgery on cardiopulmonary bypass (CPB). A sub-study will also be conducted to evaluate the pharmacokinetic (PK) profile of a single administration of RBT-1 by means of a popPK approach in subjects scheduled to undergo cardiac surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Post-Operative Complications in Cardiac Surgery
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma
Recruiting
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center, Boston, Massachusetts
Conditions: Adenocarcinoma, Pancreatic Ductal
Strategy for Improving Stroke Treatment Response
Recruiting
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Ischemic Stroke